[头颈部非黑色素皮肤癌的综合疗法]。

Magyar onkologia Pub Date : 2025-07-11 Epub Date: 2025-06-25
Adrienn Herczeg, István Fodor, Attila Füzes, Ferenc Oberna
{"title":"[头颈部非黑色素皮肤癌的综合疗法]。","authors":"Adrienn Herczeg, István Fodor, Attila Füzes, Ferenc Oberna","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Although most malignant non-melanoma skin cancers are low-risk and curable with surgical intervention, the management of locally advanced and metastasizing tumors is very challenging. Previous systemic treatment options for advanced skin cancer were limited to cytotoxic chemotherapy and anti-epidermal growth factor receptor (EGFR) therapy, with significant morbidity and poor durable response rates, but the newly emerged therapies such as Hedgehog pathway inhibitors and immunotherapies have improved not only the survival, but the patients' quality of life too. The clinical trials of neoadjuvant immunotherapies are still ongoing, but in the case of borderline resection margins or surgical removal with high morbidity or severe functional impairment, immunotherapy can be a good option for aesthetical and functional preservation and provides a long term survival with combination of oncological therapies.</p>","PeriodicalId":94127,"journal":{"name":"Magyar onkologia","volume":"69 2","pages":"173-178"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Complex therapy for non-melanotic skin cancers in the head and neck region].\",\"authors\":\"Adrienn Herczeg, István Fodor, Attila Füzes, Ferenc Oberna\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Although most malignant non-melanoma skin cancers are low-risk and curable with surgical intervention, the management of locally advanced and metastasizing tumors is very challenging. Previous systemic treatment options for advanced skin cancer were limited to cytotoxic chemotherapy and anti-epidermal growth factor receptor (EGFR) therapy, with significant morbidity and poor durable response rates, but the newly emerged therapies such as Hedgehog pathway inhibitors and immunotherapies have improved not only the survival, but the patients' quality of life too. The clinical trials of neoadjuvant immunotherapies are still ongoing, but in the case of borderline resection margins or surgical removal with high morbidity or severe functional impairment, immunotherapy can be a good option for aesthetical and functional preservation and provides a long term survival with combination of oncological therapies.</p>\",\"PeriodicalId\":94127,\"journal\":{\"name\":\"Magyar onkologia\",\"volume\":\"69 2\",\"pages\":\"173-178\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-07-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Magyar onkologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Magyar onkologia","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/25 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

虽然大多数恶性非黑色素瘤皮肤癌是低风险和可治愈的手术干预,但局部晚期和转移性肿瘤的管理是非常具有挑战性的。以往晚期皮肤癌的全身治疗选择仅限于细胞毒性化疗和抗表皮生长因子受体(EGFR)治疗,发病率高,持久反应率差,但新出现的治疗方法如刺猬通路抑制剂和免疫疗法不仅提高了生存率,而且提高了患者的生活质量。新辅助免疫治疗的临床试验仍在进行中,但在边缘切除边缘或手术切除具有高发病率或严重功能损害的情况下,免疫治疗可以是美观和功能保留的良好选择,并与肿瘤治疗相结合提供长期生存。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Complex therapy for non-melanotic skin cancers in the head and neck region].

Although most malignant non-melanoma skin cancers are low-risk and curable with surgical intervention, the management of locally advanced and metastasizing tumors is very challenging. Previous systemic treatment options for advanced skin cancer were limited to cytotoxic chemotherapy and anti-epidermal growth factor receptor (EGFR) therapy, with significant morbidity and poor durable response rates, but the newly emerged therapies such as Hedgehog pathway inhibitors and immunotherapies have improved not only the survival, but the patients' quality of life too. The clinical trials of neoadjuvant immunotherapies are still ongoing, but in the case of borderline resection margins or surgical removal with high morbidity or severe functional impairment, immunotherapy can be a good option for aesthetical and functional preservation and provides a long term survival with combination of oncological therapies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信